More than 217,000 men will be diagnosed with prostate cancer this year. About 32,000 will die. A newly approved drug can extend lives by several months but at a cost close to $100,000. CBS News ...

If a cancer drug can prolong some poor man's life by 4 months, should 93,000 of your tax dollars be spent on it? How about 93,000 of your insurance dollars? That's what Dendreon's PROVENGE does, and ...

It's been a just a day since Dendreon announced that the interim analysis of its Provenge anti-prostate cancer candidate showed some -- but not enough -- improvement in sufferers, and already the drug ...

NEW YORK (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S.

Dendreon’s Seal Beach plant: advertising campaign aimed at boosting demand for company’s flagship product A top executive of Seattle-based biotech Dendreon Corp., which has a manufacturing plant in ...

Medicare said this week it will pay for two cancer treatments with hefty price tags -- and lingering questions: Avastin, the controversial drug shot down by an Food and Drug Administration panel on ...

NEW YORK, Oct 7 (Reuters) - Interest in Dendreon Corp's Provenge vaccine to treat prostate cancer seems to be waning following recent approval of Johnson & Johnson's more-convenient and faster-acting ...

An FDA advisory committee yesterday voted 13-4 in favor of Provenge, an experimental treatment for advanced prostate cancer. The vote was hotly anticipated by cancer patients and investors in Dendreon ...

SEAL BEACH, Calif.--(BUSINESS WIRE)--Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced publication of results from ...